Therefore, we investigated the mRNA expression levels of CXC chemokine receptor 2 (CXCR2) and CXCR5, the functional receptors of CXCL13 and CXCL5; however, no significant differences in the prostate tumors were found between the FABP4−/− TRAMP-HF and TRAMP-HF groups (Figure S3). The gene discussed is CXCL13; the disease is prostate neoplasm.